Evan Shlofmitz, DO
Interventional Cardiology · Roslyn, NYNPI 1639494479
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $622,814 of the $950,745 with a category attached, or 65.5%. 42 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. 2025 is the largest year on record at $220,955, 8.9 times the $24,879 reported in 2019. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 854 payments — averaging $1113.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$237K
- Johnson & Johnson$150K
- Abbott$130K
- Shockwave Medical, Inc$113K
- Amgen$100K
- Philips North America LLC$46K
- plus $175K from 36 others
Across 64 payments — averaging $23,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$575K
- Medtronic$274K
- Shockwave Medical, Inc$240K
- Spectrawave, Inc$191K
- Cathworks, Inc.$124K
- Gentuity, LLC$96K
- plus $33K from 2 others
What the payments were for
- Royalty or licence$12,4971%
- Consulting fees$233,66025%
- Speaking & faculty fees$622,81466%
- Travel & lodging$45,8595%
- Food & beverage$33,5304%
- Education$1030%
- Other$2,2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$149,459
- Repatha$97,702
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$96,740
- Ozempic$81,420
- Wegovy$79,339
- Dragonfly OCT$50,552
- (9520) IGT Devices Undivided$40,511
- Inpefa$36,071
- GENERAL VASCULAR ACCESS$35,999
- Xience V coronary stent system$32,745
- OPTIS$30,740
- FFRct$25,526
- RYBELSUS$17,105
- Vascular Lithotripsy$16,215
- VenaSeal$12,497
- KENGREAL$10,163
- Diamondback Coronary$5,940
- HD-IVUS$5,352
- FARXIGA$4,745
- XIENCE V$3,719
How this compares
$950,745 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 110 | $151,993 |
| EliquisApixaban | 102 | $119,868 |
| Repatha SureclickEvolocumab | 150 | $94,352 |
| FarxigaDapagliflozin Propanediol | 80 | $94,149 |
| JardianceEmpagliflozin | 65 | $74,408 |
| OzempicSemaglutide | 68 | $65,276 |
| EntrestoSacubitril/Valsartan | 45 | $41,263 |
| MounjaroTirzepatide | 31 | $31,670 |
| BrilintaTicagrelor | 35 | $28,255 |
| Prasugrel Hcl | 161 | $13,575 |
| Praluent PenAlirocumab | 21 | $11,750 |
| Metoprolol Succinate | 318 | $5,612 |
| Rosuvastatin Calcium | 289 | $4,662 |
| Atorvastatin Calcium | 227 | $2,653 |
| Ezetimibe | 67 | $2,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $150,200 | $151,993110 claims |
| AstraZenecaFarxiga, Brilinta | $5,819 | $122,404115 claims |
| Boehringer IngelheimJardiance | $121 | $74,40865 claims |
| Novo NordiskOzempic | $236,568 | $65,27668 claims |
| NovartisEntresto | $72 | $41,26345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Roslyn
- David CohenRoslyn$392K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.